» Articles » PMID: 30414973

Kappa Opioid Receptors Mediate Yohimbine-induced Increases in Impulsivity in the 5-choice Serial Reaction Time Task

Overview
Journal Behav Brain Res
Date 2018 Nov 12
PMID 30414973
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Dynorphin (DYN), and its receptor, the kappa opioid receptor (KOR) are involved in drug seeking and relapse but the mechanisms are poorly understood. One hypothesis is that DYN/KOR activation promotes drug seeking through increased impulsivity, because many stimuli that induce DYN release increase impulsivity. Here, we systematically compare the effects of drugs that activate DYN/KOR on performance on the 5-choice serial reaction time task (5-CSRTT), a test of sustained attention and impulsivity. In Experiment 1, we determined the effects of U50,488 (0, 2.5, 5 mg/kg), yohimbine (0, 1.25, 2.5 mg/kg), and nicotine (0, 0.15, 0.3 mg/kg) on 5-CSRTT performance. In Experiment 2, we determined the effects of alcohol (0, 0.5, 1.0, 1.5 g/kg) on 5-CSRTT performance before and after voluntary, intermittent alcohol exposure. In Experiment 3, we determined the potential role of KOR in the pro-impulsive effects of yohimbine (1.25 mg/kg) and nicotine (0.3 mg/kg) by the prior administration of the KOR antagonist nor-BNI (10 mg/kg). Premature responding, the primary measure of impulsivity, was reduced by U50,488 and alcohol, but these drugs had a general suppressive effect. Yohimbine and nicotine increased premature responding. Yohimbine-, but not nicotine-induced increases in premature responding were blocked by nor-BNI, suggesting that impulsivity induced by yohimbine is KOR dependent. This may suggests a potential role for KOR-mediated increases in impulsivity in yohimbine-induced reinstatement.

Citing Articles

Perinatal morphine but not buprenorphine affects gestational and offspring neurobehavioral outcomes in mice.

Smith B, Hassler A, Lloyd K, Reyes T Neurotoxicology. 2023; 99:292-304.

PMID: 37981055 PMC: 10842910. DOI: 10.1016/j.neuro.2023.11.008.


Optogenetic and pharmacological interventions link hypocretin neurons to impulsivity in mice.

Tyree S, Jennings K, Gonzalez O, Li S, Nicholson J, von Heimendahl M Commun Biol. 2023; 6(1):74.

PMID: 36658362 PMC: 9852239. DOI: 10.1038/s42003-023-04409-w.


Perinatal Morphine Exposure Leads to Sex-Dependent Executive Function Deficits and Microglial Changes in Mice.

Smith B, Guzman T, Brendle A, Laaker C, Ford A, Hiltz A eNeuro. 2022; 9(5).

PMID: 36216505 PMC: 9581576. DOI: 10.1523/ENEURO.0238-22.2022.


Noradrenergic contributions to cue-driven risk-taking and impulsivity.

Chernoff C, Hynes T, Winstanley C Psychopharmacology (Berl). 2021; 238(7):1765-1779.

PMID: 33649970 DOI: 10.1007/s00213-021-05806-x.


TAAR1 agonists attenuate extended-access cocaine self-administration and yohimbine-induced reinstatement of cocaine-seeking.

Liu J, Johnson B, Wu R, Seaman Jr R, Vu J, Zhu Q Br J Pharmacol. 2020; 177(15):3403-3414.

PMID: 32246467 PMC: 7348092. DOI: 10.1111/bph.15061.


References
1.
Evenden J, Ryan C . The pharmacology of impulsive behaviour in rats VI: the effects of ethanol and selective serotonergic drugs on response choice with varying delays of reinforcement. Psychopharmacology (Berl). 1999; 146(4):413-21. DOI: 10.1007/pl00005486. View

2.
Grottick A, Higgins G . Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res. 2000; 117(1-2):197-208. DOI: 10.1016/s0166-4328(00)00305-3. View

3.
Hahn B, Shoaib M, Stolerman I . Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands. Psychopharmacology (Berl). 2002; 162(2):129-37. DOI: 10.1007/s00213-002-1005-6. View

4.
Robbins T . The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl). 2002; 163(3-4):362-80. DOI: 10.1007/s00213-002-1154-7. View

5.
Endoh T, Matsuura H, Tanaka C, Nagase H . Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992; 316:30-42. View